Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 35, 2020 - Issue 1
Submit an article Journal homepage
3,520
Views
47
CrossRef citations to date
0
Altmetric
Short Communication

Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment

Yi Lea State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, State-Local Joint Laboratory for Comprehensive Utilization of Biomass, Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang, China;b School of Pharmaceutical Sciences, Guizhou University, Guiyang, China;c Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, ChinaView further author information
,
Yiyuan Ganb School of Pharmaceutical Sciences, Guizhou University, Guiyang, ChinaView further author information
,
Yihong Fub School of Pharmaceutical Sciences, Guizhou University, Guiyang, ChinaView further author information
,
Jiamin Liub School of Pharmaceutical Sciences, Guizhou University, Guiyang, ChinaView further author information
,
Wen Lib School of Pharmaceutical Sciences, Guizhou University, Guiyang, ChinaView further author information
,
Xue Zoud Clinical Research Center, Affiliated Hospital of Guizhou Medical University, Guiyang, ChinaView further author information
,
Zhixu Zhoub School of Pharmaceutical Sciences, Guizhou University, Guiyang, China;c Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China;d Clinical Research Center, Affiliated Hospital of Guizhou Medical University, Guiyang, ChinaView further author information
,
Zhenchao Wangb School of Pharmaceutical Sciences, Guizhou University, Guiyang, China;c Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1859-0128View further author information
ORCID Icon,
Guiping Ouyanga State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, State-Local Joint Laboratory for Comprehensive Utilization of Biomass, Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang, China;b School of Pharmaceutical Sciences, Guizhou University, Guiyang, China;c Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, ChinaCorrespondence[email protected]
View further author information
&
Longjia Yanb School of Pharmaceutical Sciences, Guizhou University, Guiyang, China;c Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China;d Clinical Research Center, Affiliated Hospital of Guizhou Medical University, Guiyang, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 555-564 | Received 17 Dec 2019, Accepted 07 Jan 2020, Published online: 22 Jan 2020

References

  • Chang SC, Lai YC, Chang CY, et al. Concomitant genetic alterations are associated with worse clinical outcome in EGFR mutant NSCLC patients treated with tyrosine kinase inhibitors. Transl Oncol 2019;12:1425–31.
  • Gan Y, Shi C, Inge L, et al. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 2010;29:4947–58.
  • Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911–4.
  • Higgins B, Smith M, Rashed M, et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 2004;15:503–12.
  • Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR Inhibitors. Sci Transl Med 2011;3:75–101.
  • Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nat Med 2015;21:560–2.
  • Bhattarai D, Jung JH, Han S, et al. Design, synthesis and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors. Eur J Med Chem 2017;125:1036–50.
  • Amir M, Ali I, Hassan MZ. Design and synthesis of some new quinazolin-4-(3H)-ones as anticonvulsant and antidepressant agents. Arch Pharmacal Res 2013;36:61–8.
  • Wei M, Chai WM, Wang R, et al. Quinazolinone derivatives: synthesis and comparison of inhibitory mechanisms on α-glucosidase. Bioorg Med Chem 2017;25:1303–8.
  • Sonawane V, Mohd Siddique MU, Jadav SS, et al. Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy. Eur J Med Chem 2019;165:115–32.
  • Dohle W, Jourdan FL, Menchon G, et al. Quinazolinone-based anticancer agents: synthesis, antiproliferative SAR, antitubulin activity, and Tubulin co-crystal structure. J Med Chem 2018;61:1031–44.
  • Yin S, Tang C, Wang B, et al. Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold. Eur J Med Chem 2016;120:26–36.
  • Tumma R, Siliveri S, Vamaraju HB, et al. Synthesis, biological evaluation and molecular docking studies of isoxazole synchronized quinazolinone derivatives. J Pharm Res. 2017;11:895–902.
  • Shi L, Wu TT, Wang Z, et al. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2. Bioorg Med Chem 2014;22:4735–44.
  • Patel HM, Pawara R, Ansari A, et al. Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle. Bioorg Med Chem 2017;25:2713–23.
  • Zayed MF, Rateb HS, Ahmed S, et al. Quinazolinone-amino acid hybrids as dual inhibitors of EGFR kinase and Tubulin polymerization. Molecules 2018;23:1699–715.
  • Aggarwal S, Sinha D, Tiwari AK, et al. Studies for development of novel quinazolinones: new biomarker for EGFR. Spectrochim Acta A Mol Biomol Spectrosc 2015;143:309–18.
  • Hanusek J, Rosa P, Drabina P, et al. Cyclizatioon of 2-benzoylamino-N-methyl-thiobenzamides to 3-methyl-2-phenylquinazolin-4-thiones. J Heterocyclic Chem 2006;43:1281–5.
  • Ma CC, Zhang CM, Tang L, et al. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kdelta and PI3Kdelta/gamma inhibitors. Eur J Med Chem 2018;151:9–17.
  • Zhang Y, Chen L, Li X, et al. Novel 4-arylaminoquinazolines bearing N,N-diethyl(aminoethyl)amino moiety with antitumor activity as EGFRwt-TK inhibitor. J Enzyme Inhib Med Chem 2019;34:1668–77.
  • Yan L, Wang H, Chen Y, et al. Synthesis and structure-activity relationship study of diaryl[d,f][1,3]diazepines as potential anti-cancer agents. Mol Divers 2018;22:323–33.
  • Safavi M, Ashtari A, Khalili F, et al. Novel quinazolin-4(3H)-one linked to 1,2,3-triazoles: synthesis and anticancer activity. Chem Biol Drug Des 2018;92:1373–81.
  • Park JH, Liu Y, Lemmon MA, et al. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J 2012;448:417–23.
  • Fabian MA, Biggs IIW, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329–36.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.